Drug profile · INN
clonidine
APO-CLONIDINE
clonidine (APO-CLONIDINE) is a adrenergic receptor alpha-2 agonist. Associated with Apotex Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — clonidine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 3
- Programs
- 8
- Data quality
- 0.84
Quick answer
clonidine (APO-CLONIDINE) is a adrenergic receptor alpha-2 agonist. Associated with Apotex Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor alpha-2 agonist
Primary target: Adrenergic receptor alpha-2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11090290
Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
granted -
US 10675271
Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy
granted -
US 10450340
3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
granted
Frequently asked questions
What is clonidine?
clonidine (APO-CLONIDINE) is a adrenergic receptor alpha-2 agonist. Associated with Apotex Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for clonidine?
APO-CLONIDINE is a marketed brand name for clonidine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of clonidine?
clonidine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.